FDA Approves Avapritinib (Ayvakit) for GIST with Mutation FDA Approves Avapritinib (Ayvakit) for GIST with Mutation

The new product is indicated for use in gastrointestinal stromal tumors (GIST) that harbor a mutation, which renders these tumors resistant to standard therapy.FDA Approvals

Source: Medscape Hematology-Oncology Headlines - January 10, 2020 Category: Cancer & Oncology Tags: Hematology-Oncology News Alert Source Type: news